EGFR and neoplasm: Lack of PTEN protein expression significantly associated with a high risk of progression in the first-line anti-EGFR setting, with a time to progression of 4.2 months versus 9.4 months in patients whose tumours expressed PTEN (HR = 3.7, CI95% 1.1–13.1, p = 0.03).